Mesothelioma Clinical Trials Now Back on Course

August 11, 2020 By Melissa Soria

A number of treatment centers, such as Brigham and Women’s Hospital in Boston, delayed mesothelioma clinical trials at the start of the pandemic. Others, such as the Pacific Mesothelioma Center in Los Angeles, continued screening patients, but on a limited basis. Now, many mesothelioma clinical trials are resuming regular screening and enrollment measures for mesothelioma patients…

New Mesothelioma Clinical Trial Involves Keytruda

July 22, 2020 By Melissa Soria

Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The clinical trial will involve pembrolizumab, also known by the brand name Keytruda and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma…

Dr. Nicholas Vogelzang Discusses Developments in Mesothelioma Treatment

June 7, 2018 By swarren

Dr. Nicholas Vogelzang, long respected for his groundbreaking work in mesothelioma treatment, was inducted to the Giants of Cancer Care®  in a special ceremony at Adler Planetarium on May 31. This honor comes as recognition of Dr. Vogelzang’s revolutionary research and success treating genitourinary cancers including bladder and kidney cancer. The award celebrates leaders in…

UNIVERSITY OF CHICAGO MESOTHELIOMA DRUG TRIALS NEW HOPE FOR MESOTHELIOMA PATIENTS

July 29, 2016 By Vogelzang Law Webmaster

A clinical study of malignant pleural mesothelioma patients treated with investigational cancer vaccine CRS-207 at University of Chicago Medical Center, UCSF’s cancer center, the Moffitt Cancer Center in Tampa, the Abramson Cancer Center in Philadelphia and the National Cancer Institutein Bethesda, Maryland has shown promising results in shrinking tumors. CRS-207 caused tumor shrinkage in 85% of…